Sotyktu (deucravacitinib) / BMS - LARVOL DELTA

Conversion of Conjunctival Nevus to Melanoma in a Patient Taking the TYK2 Inhibitor Deucravacitinib. (PubMed, Cornea) - "Deucravacitinib-mediated inhibition of tyrosine kinase 2 (TYK-2) disrupts signaling of cytokines interferon alpha (IFN-α), interleukin (IL)-12 and IL-23, providing a theoretical mechanism for increased risk of malignancy while taking the drug. In this case, the temporal relation between starting deucravacitinib treatment and the rapid growth of a conjunctival melanoma arising from a nevus is concerning for a protumor effect of this immunomodulatory drug. Patients with ocular lesions at risk of malignant transformation should perhaps be closely monitored while on deucravacitinib therapy until more is known regarding the degree of risk of malignant transformation because of immunomodulation from TYK2 inhibition."

Journal • Dermatology • Eye Cancer • Immunology • Melanoma • Ocular Melanoma • Oncology • Psoriasis • Solid Tumor • IFNA1 • IL23A • TYK2

Deucravacitinib Adherence Study (clinicaltrials.gov) - P=N/A | N=40 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jul 2025 ➔ Dec 2025

Enrollment closed • Trial primary completion date • Dermatology • Immunology • Psoriasis

Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Alopecia • Immunology

Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis. (PubMed, Clin Rev Allergy Immunol) - "The network meta-analysis indicated that compared with standard therapy, telitacicept (OR 5.2, 95% CI 1.4-20.0) demonstrated superior efficacy in achieving SRI4 response, deucravacitinib (OR 1.6, 95% CI 1.0-2.5), and anifrolumab (OR 1.6, 95% CI 1.3-2.0) all exhibited significant BICLA response in moderate-to-severe SLE patients. For patients with elevated baseline IFN signatures, anti-type I interferon biologics such as anifrolumab and sifalimumab are recommended to maximize clinical benefits. The reliance on indirect comparisons necessitates cautious interpretation of these findings, so further research should prioritize direct head-to-head trials to validate the efficacy and safety profiles of these biologics."

Clinical • Journal • Retrospective data • Review • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anifrolumab and deucravacitinib as novel therapeutic options for cutaneous lupus erythematosus: utility in multi-refractory patients and safety regarding latent tuberculosis infection (EADV 2025) - No abstract available

Clinical • Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Respiratory Diseases • Tuberculosis

Icotrokinra Demonstrated Superior Responses Compared With Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies (EADV 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Real-World Treatment Switch Rates for Risankizumab Compared With Deucravacitinib in Patients With Psoriasis (EADV 2025) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

New Hope: Selective TYK-2 Inhibition in Psoriasis - Clinical Potential of Deucravacitinib (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis • TYK2

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with plaque psoriasis in a community setting: efficacy and safety results from a phase 4 multicenter, randomized, double-blinded, placebo-controlled study (ARTISTYK) (EADV 2025) - No abstract available

Clinical • P4 data • Dermatology • Immunology • Psoriasis • TYK2

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with plaque psoriasis: patient-reported outcomes in a phase 4 multicenter, randomized, double-blinded, placebo-controlled study (ARTISTYK) (EADV 2025) - No abstract available

Clinical • P4 data • Patient reported outcomes • Dermatology • Immunology • Psoriasis • TYK2

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: 52-week efficacy and safety results of a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP) (EADV 2025) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Psoriasis • TYK2

Real-world effectiveness and safety of deucravacitinib for adult patients with plaque psoriasis: A 16-week multicenter retrospective study of monotherapy and combination therapy (EADV 2025) - No abstract available

Combination therapy • Monotherapy • Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Dermatology • Immunology • Psoriasis

Acneiform eruption secondary to deucravacitinib: a case series (EADV 2025) - No abstract available

Clinical • Dermatology

A case report of bullous pemphigoid induced by deucravacitinib in the treatment of psoriasis (EADV 2025) - No abstract available

Case report • Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Psoriasis

Improvement of extragenital lichen sclerosus with deucravacitinib (EADV 2025) - No abstract available

Dermatology

Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis (EADV 2025) - No abstract available

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and safety of deucravacitinib in patients with discoid lupus erythematosus (DLE) and/or subacute cutaneous lupus erythematosus (SCLE): results from PAISLEY CLE, a global, phase 2 randomized, double-blind, placebo-controlled trial (EADV 2025) - No abstract available

Clinical • P2 data • Cutaneous Lupus Erythematosus • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Synthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165). (PubMed, J Labelled Comp Radiopharm) - "Tyrosine kinase 2 (TYK2) is a member of the Janus (JAK) family of non-receptor kinases that modulate the production of inflammatory cytokines. The synthesis of 14C-radiolabeled and stable-isotope labeled variants of deucravacitinib is described in this publication."

Journal • Dermatology • Immunology • Psoriasis • TYK2

A Validated Quantitative LC-MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The recovery of deucravacitinib ranged from 95.34% to 103.80% and remained stable under different conditions. After successful validation, the method was used for pharmacokinetic profiling of deucravacitinib in rats following oral administration."

Journal • PK/PD data • Preclinical • Dermatology • Immunology • Psoriasis • TYK2

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally (Businesswire) - "Bristol Myers Squibb...announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026. This latest regulatory milestone is in addition to the sNDA acceptances by China’s Center for Drug Evaluation of National Medical Products Administration and Japan's Ministry of Health, Labour and Welfare for Sotyktu for the treatment of adults with active psoriatic arthritis. The European Medicines Agency has also validated Bristol Myers Squibb's Type II variation application to expand the indication for Sotyktu to include this disease...The regulatory applications are based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of Sotyktu in adults with active psoriatic arthritis."

FDA filing • PDUFA • Psoriatic Arthritis

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial. (PubMed, J Dermatol) - P3 | "Deucravacitinib was associated with meaningful and sustained improvements in psoriasis symptoms and signs and in quality of life in Asian patients with moderate to severe plaque psoriasis. Trial Registration: ClinicalTrials.gov identifier: NCT04167462."

Journal • Dermatology • Immunology • Psoriasis • TYK2

Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "Therefore, we consider that deucravacitinib may have contributed to the improvement of IP by blocking these signaling pathways, thereby suppressing chronic T cell-driven inflammation and fibrosis. Further accumulation of cases and continued research will be essential in advancing discussions on the clinical utility of TYK2 inhibitors in IP management."

Journal • Dermatology • Fibrosis • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Pneumonia • Psoriasis • Pulmonary Disease • Respiratory Diseases • IL17A • IL23A • TYK2

Identifying Predictive Factors for Complete Skin Clearance at Week 52 by Deucravacitinib in Moderate-to-Severe Psoriasis: A Prospective Observational Study. (PubMed, Cureus) - "A BMI < 22.9 kg/m² and age < 61 years independently identify patients most likely to obtain CSC at week 52 with deucravacitinib. These cut‑offs can support early treatment selection and stratification in future prospective trials, facilitating personalized care for psoriasis."

Biomarker • Journal • Observational data • Dermatology • Immunology • Psoriasis • TYK2

Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatitis • Dermatology • Dermatomyositis • Immunology • Myositis • Rheumatology